Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 3/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965247 | 0.92 | MAPK1 (0.40) | CHEK2GPR119MAPK1GSK3BALOX5AP | |
| SCHEMBL29964044 | 0.91 | CHEK2 (0.42) | CHEK2GPR119ALKMAPK1HTT | |
| SCHEMBL29964420 | 0.91 | CHEK2 (0.49) | CHEK2GPR119MAPK1GSK3BALOX5AP | |
| SCHEMBL29964866 | 0.91 | CHEK2 (0.46) | CHEK2GPR119ALKHTTHRH3 | |
| SCHEMBL31079292 | 0.91 | GPR119 (0.46) | CHEK2GPR119ALKMAPK1GSK3B | |
| SCHEMBL29964262 | 0.90 | MAPK1 (0.45) | GPR119MAPK1GSK3BHTTALOX5AP | |
| SCHEMBL29964484 | 0.90 | CHEK2 (0.44) | CHEK2MAPK1GSK3B | |
| SCHEMBL29964825 | 0.90 | PDE4B (0.45) | CHEK2GPR119GSK3BHTTALOX5AP | |
| SCHEMBL29965076 | 0.90 | GPR119 (0.42) | CHEK2GPR119MAPK1GSK3B | |
| SCHEMBL31079424 | 0.89 | GPR119 (0.39) | CHEK2GPR119MAPK1GSK3BALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | CHEK2 162/4885GPR119 1816/4885ALK 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.